G.R. No. 182358 - Department of Health vs. Phil Pharmawealth, Inc.

Case Summary (G.R. No. 182358)

Key Dates and Procedural Posture

AO No. 27 (1998) and AO No. 10 (2000) set DOH accreditation rules; AO 10 shortened accreditation to two years and allowed recall/suspension/revocation under specified procedures. AO 66 later amended AO 10.
August 28, 2000: Memorandum No. 171‑C enumerated sanctions for accredited suppliers with adverse findings.
October 27, 2000: DOH meeting where BFAD’s Report on Violative Products was distributed and accredited suppliers were directed to submit explanations within 10 days (until November 6, 2000).
November 13, 2000: PPI sent a belated letter referring the Report to its lawyers; no request for extension or timetable for reply.
November 23, 2000: Undersecretary Galon suspended PPI’s accreditation for two years.
December 28, 2000: PPI filed Civil Case No. 68200 in the Regional Trial Court (RTC) of Pasig seeking nullification of DOH issuances, damages, and injunctive relief.
RTC dismissed the case as a suit against the State; Court of Appeals (CA) reversed and remanded; the Supreme Court granted the petition and ordered dismissal.

Applicable Law and Constitutional Basis

The decision is grounded on the 1987 Philippine Constitution’s principle that the State may not be sued without its consent. Relevant statutory and administrative authorities cited in the decision include RA No. 3720 (Food, Drug, and Cosmetic Act), Executive Order No. 175 (amending RA 3720), Administrative Orders (AO 27, AO 10, AO 66), Memorandum No. 171‑C, Memorandum No. 209 (DOH), and the Administrative Code (authority of the Health Secretary and Undersecretary to supervise BFAD).

Factual Background: DOH Actions and PPI’s Response

AO 27 (1998) established accreditation rules for government suppliers; AO 10 (2000) amended AO 27 reducing accreditation to two years and permitting recall/suspension/revocation by the Accreditation Committee; AO 66 later required deliberation, hearing, and notice for recall/suspension/revocation. BFAD compiled a Report on Violative Products identifying several PPI products as unfit for human consumption. At the October 27, 2000 meeting Undersecretary Galon directed 24 accredited suppliers, including PPI, to submit explanations within ten days. PPI instead sent a November 13, 2000 letter indicating referral to counsel without indicating when a reply would be filed. On November 23, 2000, Galon suspended PPI’s accreditation for two years pursuant to AO 10 and Memorandum No. 171‑C.

PPI’s Complaint and Relief Sought

PPI filed suit in the RTC seeking to declare AO 10, Memorandum No. 171‑C, Undersecretary Galon’s suspension letter, and AO 14 null and void for contravening Section 26(d) of RA 3720 and EO 175 (which require notice and the opportunity to be heard before BFAD). PPI alleged denial of substantive and administrative due process and sought moral and exemplary damages, attorney’s fees, costs, and injunctive relief.

Defendants’ Answer and DOH Position

The DOH, Secretaries Romualdez and Dayrit, and Undersecretary Galon maintained that the suspension was justified because BFAD found PPI’s drugs substandard. They asserted DOH authority over health policy, accreditation, and regulation of medicines, and argued PPI failed to timely submit the required comment within the ten‑day period. They contended that due process was afforded and that immediate action was necessary to protect public health. They also moved to dismiss on grounds that the suit was effectively against the State and that the complaint was improperly verified and that PPI’s corporate officer lacked authority to file suit.

RTC Ruling and CA Decision

The RTC dismissed the complaint as a suit against the State and therefore barred by state immunity. The CA reversed, holding dismissal premature: the CA found a sufficient cause of action alleging acts beyond the scope of authority and that petitioners were sued in their personal capacities. The CA reasoned that the trial court should have deferred resolution of the motion to dismiss and permitted further proceedings to determine whether the action was against the State or against officials personally.

Issue Presented to the Supreme Court

Whether Civil Case No. 68200 must be dismissed for being a suit against the State, given the prayer for damages that would impose financial liability on the government and the nature of the DOH officials’ actions.

Legal Principles: Doctrine of Non‑Suability and Its Exceptions

The Court reiterated that under the 1987 Constitution the State may not be sued without its consent; this doctrine reflects sovereign immunity and is not absolute. Consent can be express by statute or implied (for example, when the State enters into a contract or initiates litigation, subject to qualifications distinguishing proprietary from sovereign acts). Statutory waivers of immunity are strictly construed. The doctrine extends to unincorporated government agencies that perform governmental functions; such agencies lack separate juridical personality and enjoy immunity from suit when performing sovereign functions. The immunity also extends to complaints against public officials for acts performed in their official capacities, unless the official acted ultra vires or in bad faith and the claim is against them personally.

Application: DOH as an Unincorporated Agency and Financial Liability

The Court concluded that the DOH, an unincorporated agency performing governmental functions, may validly invoke state immunity because it did not consent to be sued. PPI’s complaint specifically sought monetary relief from DOH and the officials jointly and severally (moral damages, exemplary damages, attorney’s fees, and costs). A judgment awarding such damages would impose a financial charge on the State requiring appropriation from the national trea

Case Syllabus (G.R. No. 182358)

Case Citation and Decision

Reported at 704 Phil. 432; 109 OG No. 46, 7754 (November 18, 2013).
G.R. No. 182358; Decision promulgated February 20, 2013 by the Second Division of the Supreme Court of the Philippines.
Decision penned by Justice Del Castillo. Concurring: Carpio (Chairperson), Brion, Peralta, and Perez, JJ. (Per raffle dated February 4, 2013).
Petition for Review on Certiorari assailed the Court of Appeals Decision dated October 25, 2007 in CA-G.R. CV No. 85670 and the CA Resolution dated March 31, 2008 denying petitioners’ Motion for Reconsideration.

Parties

Petitioners: The Secretary of Health (initially Alfredo G. Romualdez; later Secretary Manuel Dayrit) and Ma. Margarita M. Galon (Undersecretary).
Respondent: Phil Pharmawealth, Inc. (PPI).
Other named parties in trial pleadings: former Secretary Romualdez, Secretary Dayrit, Undersecretary Galon, and the Department of Health (DOH).

Central Legal Question

Whether Civil Case No. 68200 should be dismissed for being a suit against the State (i.e., barred by the doctrine that “the State may not be sued without its consent”).

Factual Background — Administrative Issuances and Actions

December 22, 1998: DOH Administrative Order (AO) No. 27, series of 1998, issued by Secretary Alfredo G. Romualdez, setting guidelines/procedure for accreditation of government suppliers of pharmaceutical products; accreditation valid for three years but subject to annual review.
January 25, 2000: Secretary Romualdez issued AO No. 10, series of 2000 amending AO 27:
- Section VII reduced accreditation period for government pharmaceutical suppliers to two years.
- AO 10 provided that accreditation may be recalled, suspended or revoked after due deliberation and proper notice by the DOH Accreditation Committee, through its Chairman.
AO 66, series of 2000 later amended Section VII of AO 10 to require recall/suspension/revocation only after due deliberation, hearing and notice by the DOH Accreditation Committee, through its Chairman.
August 28, 2000: DOH Memorandum No. 171-C provided a list and category of sanctions to be imposed on accredited government suppliers in case of adverse findings regarding their products (e.g., substandard, fake, or misbranded) or violations committed during accreditation.
In line with Memorandum No. 171-C, Undersecretary Ma. Margarita M. Galon issued DOH Memorandum No. 209, series of 2000, inviting representatives of 24 accredited drug companies, including PPI, to a meeting on October 27, 2000.
At the October 27, 2000 meeting, Undersecretary Galon distributed the Bureau of Food and Drugs’ “Report on Violative Products,” which contained adverse findings: BFAD found that certain PPI products being sold to the public were unfit for human consumption.
During the meeting, the 24 companies were directed to submit explanations on the adverse findings within 10 days (i.e., until November 6, 2000).

PPI’s Response and DOH Action

PPI did not submit a written explanation within the 10-day period.
November 13, 2000: PPI, through Atty. Alan A.B. Alambra (Vice-President for Legal and Administrative Affairs), sent a belated letter to Undersecretary Galon stating that PPI had “instructed our lawyers to prepare on our behalf the appropriate reply” and that “Our lawyers in time shall revert to you and furnish you the said reply,” but did not indicate when the reply would be submitted or seek extension nor explain the delay.
November 23, 2000: Undersecretary Galon, in a letter-reply, found PPI’s November 13 letter “untenable” and informed PPI that, effective immediately, its accreditation was suspended for two years pursuant to AO 10 and Memorandum No. 171-C.
December 14, 2000: PPI, through counsel, challenged the suspension, asserting that suspension pursuant to Section VII of AO 10 was illegal and null and void because it arrogated powers granted to the BFAD under Republic Act No. 3720 and Executive Order No. 175; PPI also contended it was suspended without notice and hearing, violating substantive and administrative due process, and demanded DOH desist from implementing suspension.

Pleadings and Relief Sought by PPI

December 28, 2000: PPI filed a Complaint in the Regional Trial Court (RTC) of Pasig City seeking to declare certain DOH administrative issuances null and void, with prayer for damages and injunction. Docketed Civil Case No. 68200, raffled to Branch 160.
February 8, 2002: PPI filed an Amended and Supplemental Complaint impleading Secretary Manuel Dayrit; alleged that AO 10, Memorandum No. 171-C, Undersecretary Galon’s November 23, 2000 suspension letter, and AO 14, series of 2001 are null and void for contravening Section 26(d) of RA 3720 (as amended by EO 175) which guarantees notice and opportunity to be heard before the BFAD.
Damages prayed: moral damages of P5,000,000; exemplary damages of P1,000,000; attorney’s fees of P1,000,000; and costs of suit. PPI also prayed for temporary and permanent injunctive relief.

Respondents’ (DOH and Officials’) Pleadings and Arguments

DOH, Romualdez, Dayrit, and Galon moved to dismiss, contending:
- The case is essentially a suit against the State; the State was not given consent to be sued.
- The Complaint was improperly verified and the corporate officer lacked authority to commence suit (no board resolution granting authority to VP Alambra).
- PPI’s accreditation was suspended because BFAD found most of PPI’s drugs to be substandard; DOH acted within its mandate to protect public health.
- PPI was afforded the opportunity to present its side within the 10-day period but failed to do so; its November 13 letter was not a substantive reply.
- Due process was afforded; immediate action was necessary to stop distribution of substandard drugs posing serious public health risk.

Trial Court Ruling

January 8, 2001: RTC partially granted PPI’s prayer for a temporary restraining order but only covering PPI products not included in the BFAD list of violative products.
June 14, 2004: RTC, Branch 160, issued an Order dismissing Civil Case No. 68200, declaring it a case instituted against the State and applying state immunity from suit. PPI’s motion for reconsideration was denied.

Court of Appeals Ruling

October 25, 2007 Decision (CA-G.R. CV No. 85670): CA reversed the RTC and remanded the
...continue reading